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Epidemiological  studies  have  demonstrated  that  the  majority  of  human  individuals  exposed  to  infec-
tion  with  Echinococcus  spp.  eggs  exhibit  resistance  to  disease  as  shown  by either  seroconversion  to
parasite—speciﬁc  antigens,  and/or  the  presence  of  ‘dying  out’  or ‘aborted’  metacestodes,  not  including
hereby  those  individuals  who  putatively  got  infected  but  did  not  seroconvert  and  who  subsequently
allowed  no  development  of  the pathogen.  For  those  individuals  where  infection  leads  to  disease,  the
developing  parasite  is  partially  controlled  by host  immunity.  In  infected  humans,  the type of immune
response  developed  by the  host  accounts  for the  subsequent  trichotomy  concerning  the  parasite  devel-
opment:  (i) seroconversion  proving  infection,  but  lack  of any  hepatic  lesion  indicating  the  failure  of the
parasite  to establish  and  further  develop  within the  liver;  or resistance  as shown  by  the  presence  of  fully
calciﬁed  lesions;  (ii)  controlled  susceptibility  as  found  in  the  “conventional”  alveolar  echinococcosis  (AE)
patients  who  experience  clinical  signs  and  symptoms  approximately  5–15  years  after  infection,  and  (iii)
uncontrolled  hyperproliferation  of  the  metacestode  due  to  an  impaired  immune  response  (AIDS  or  other
immunodeﬁciencies).  Immunomodulation  of  host  immunity  toward  anergy  seems  to  be  triggered  by
parasite  metabolites.  Beside  immunomodulating  IL-10,  TGF-driven  regulatory  T cells  have  been shown
to play  a crucial  role  in  the parasite-modulated  progressive  course  of  AE.  A novel  CD4+CD25+  Treg  effec-
tor molecule  FGL2  recently  yielded  new  insight  into  the  tolerance  process  in  Echinococcus  multilocularis
infection.
©  2015  Elsevier  B.V.  All  rights  reserved.ontents
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. Introduction AE ﬁrst affects the liver (Stojkovic et al., 2014), with a parasite tissueAlveolar echinococcosis (AE) is one of the most severe
elminthic diseases, caused by infection with the metacestode or
arval stage of the fox tapeworm Echinococcus multilocularis.  Human
∗ Corresponding author at: Institute of Parasitology, Vetsuisse Faculty and Faculty
f  Medicine, University of Bern, Länggass-Strasse 122, CH-3001 Bern, Switzerland.
E-mail address: bruno.gottstein@vetsuisse.unibe.ch (B. Gottstein).
ttp://dx.doi.org/10.1016/j.vetpar.2015.07.029
304-4017/© 2015 Elsevier B.V. All rights reserved.continuously proliferating and inﬁltrating, thus forming a growing
hepatic lesion that consists of a large conglomerate of parasite vesi-
cles, which are intermingled with mainly host connective tissue
and immune cells. Inﬂammation and immunopathology is scarce,
indicating that the parasite actively modulates the host innate and
immune reaction. Similar to malignant tumors, metastasis forma-
tion into other organs can take place at a later stage of infection
(Vuitton and Gottstein, 2010). Due to the malignant nature with
inﬁltrative growth and metastatic spread characteristics, AE may
104 B. Gottstein et al. / Veterinary Parasitology 213 (2015) 103–109
Fig. 1. Hepatic lesions formed upon E. multilocularis infection can be classiﬁed into the following three presentations: (A) “resistant” AE as shown by the presence of ‘dying
out’  or ‘aborted’ metacestodes; (B) controlled susceptibility as shown by a slowly growing metacestode tissue — this group refers to immunocompetent AE patients, and
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iC)  uncontrolled hyperproliferation of the metacestode due to an impaired immun
ransplantation. Upper picture line presents typical CT features of the three classes
ause premature death in advanced stages. However, in Europe,
hanks to life-long administration of the benzimidazoles albenda-
ole and/or mebendazole in those patients who cannot beneﬁt from
adical surgical resection of the lesions, i.e. two third of patients,
t has become a chronic disease, with signiﬁcant impairment of
uality of life. Numerous complications occur in these patients,
ncluding biliary obstruction with jaundice, septicaemia due to
epeated cholangitis and bacterial super-infection of necrotic cavi-
ies in the lesion, portal hypertension, chronic Budd-Chiari disease,
econdary biliary cirrhosis, as well as stroke, pulmonary compli-
ations, and a variety of diseased conditions related to distant
etastases (Stojkovic et al., 2014).
Radical surgical removal of hepatic lesions is the optimal treat-
ent option, but is feasible in only about 30% of the patients
Stojkovic et al., 2014). In advanced stages of AE, surgery is often
ncomplete due to the diffuse inﬁltration of metacestode tissue
nto non-resectable structures or sites. The currently available
hemotherapy, based on the benzimidazole derivatives albenda-
ole and mebendazole, has clearly increased the life expectancy of
ffected patients, and was shown to be effective in 55–97% of AE
ases (Torgerson et al., 2010; Piarroux et al., 2011; Stojkovic et al.,
014).
Epidemiological studies have demonstrated that the majority
f human individuals exposed to infection with E. multilocularis
ggs exhibit resistance to disease as shown by either seroconver-
ion to parasite-speciﬁc antigens and maintenance of a seropositive
tatus, and/or the presence of ‘dying out’ or ‘aborted’ metaces-
odes (Rausch et al., 1987; Bresson-Hadni et al., 1994; Romig et al.,
999; Gottstein et al., 2001). For those individuals where infec-
ion leads to disease, the developing parasite is partially controlled
y host immunity: in the case of immunocompetence, a slowly
rowing metacestode is observed, referring to that form of AE
here ﬁrst clinical signs appear years after infection. In the case of
mpaired immunity, caused by AIDS, other immunodeﬁciencies oronse, including AIDS or other immunodeﬁciencies, e.g. following orthotropic liver
r picture line shows typical native liver lesions as presenting after surgery.
immunosuppressing therapies such as following organ transplan-
tation, cancer chemotherapy, or chronic inﬂammatory diseases, an
uncontrolled proliferation of the metacestode is observed, lead-
ing to a more rapidly progressing disease status (Chauchet et al.,
2014).
One of the frequently encountered questions raised by clinicians
is, how many people infected with E. multilocularis eggs will effec-
tively develop disease (AE) (→ see Fig. 1b), and how many exhibit
resistance to disease; and among the infected “resistant” individ-
uals, how many present early abortion of infection (i.e. no lesion
detectable at all) and how many present spontaneous late abortion
(i.e. fully calciﬁed lesions still detectable by imaging procedures)
(→ see Fig. 1a). So far, only a very rough approach to answer these
questions can be attempted, i.e. based on the following reﬂections:
In the study of Gottstein et al. (2001) carried out with healthy
Swiss blood donors living in a hyperendemic area of Switzerland, a
rounded seroprevalence of 0.2% was found (Table 1), using a highly
speciﬁc serological test (Em2-ELISA: 99% speciﬁcity in Gottstein
et al., 1993; 100% speciﬁcity in Gottstein, 1989). In Switzerland,
for the same time period, the annual incidence was 0.2 AE cases
per 100,000 inhabitants, which equals 0.0002% in percent of the
population. As AE-experts repeatedly stated that the time inter-
val between infection (=plus/minus time-point of seroconversion)
and diagnosis of symptomatic disease ranges between 5 and 15
years (mean 10 years), we can correct the annual case incidence
by a factor of 10, so as to merge both serological and clinical base-
lines.Based on this theoretical approach (serological prevalence of
0.2%, corrected clinical prevalence of 0.002%), one can conclude that
from 100 AE-seropositive people, only one person will develop dis-
ease, and the other 99 will appear as “resistant” to disease. The
subsequent question on how many seropositive resistant individ-
uals will present hepatic “died-out” lesions, and how many will
remain “negative” in any imaging aspects, one can again use the
work of Gottstein et al. (2001) to perform a rough estimation: In this
B. Gottstein et al. / Veterinary Parasitology 213 (2015) 103–109 105
Table  1
Epidemiological studies investigating selected human populations for infection with E. multilocularis. Serological screening was combined with imaging procedures. Each
study  was  differently designed, and the serological tools used were not standardized; thus comparison of ﬁndings can only be relied on a few basic parameters. For serology,
we  selected the Em2-ELISA as consistent used in all of the studies included in this table.
Study Group investigated No. of people
investigated
No. of AE cases No. of abortive
cases
No. of
Em2-seropositive
inapparent casesa
Ratio of abortives
versus
Em2-positives plus
abortives (in %)
Gottstein et al. (1987) Healthy blood donors,
Switzerland
17,166 2 b 4 –
Bresson-Hadni et al. (1994) Selected population at
risk, France
7,884 8 5 49 9
Romig et al. (1999) Selected population at
risk, Germany
2,560 1 2 9 18
Gottstein et al. (2001) Healthy blood donors,
Switzerland
2,943 0 1 3 25
Bartholomot et al. (2002) Selected population at
risk, China
2,482 84 451 c –
a Initial seropositivity was  conﬁrmed by subsequent investigations, and lack of AE lesion formation was conﬁrmed by appropriate imaging procedures.
b In 1987, clinical imaging did not yet know about the occurrence of abortive AE cases, thus respective documentation is lacking.
c Serology was  not consistently carried out with all study participants.
1Experimental primary infection in the murine model showed that mice seroconverted approximately between 9 weeks (Matsumoto et al., 2010) and 8 weeks (Pater et al.,
1998) after peroral egg infection For the present calculation, we assumed that every infected person who subsequently developed AE also serocoverted, as evidenced by the
high  serodiagnostic sensitivity of E. multilocularis tests. We  have to mention that we  do not know how many people living in an endemic area actually ingest infective parasite
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tggs  without subsequent seronversion and parasite development. Such people are
pproach as done here.
tudy, 4 AE-seropositive blood donors were detected that under-
ent subsequently multiple imaging follow-up investigations of
heir liver. One (25%) of these four people presented a typical
mall and fully-calciﬁed lesion (indicative for a died-out, aborted
E), while the three other E. multilocularis seropositive individu-
ls remained repeatedly “negative” by ultrasonography (US) and
omputed tomography (CT) for multiple following years. As shown
n Table 1, relatively similar ﬁndings were reported in a French
tudy (Bresson-Hadni et al., 1994), where 9% (5 out of 54) E. mul-
ilocularis seropositive individuals presented abortive lesions, and
n another German study (Romig et al., 1999), 18% (2 out of 11)
f the seropositives were considered abortive cases. Combining
he four European studies listed in Table 1, one can summarize
hat within a population of 30,553 people tested, 11 active asymp-
omatic AE cases were determined (asymptomatic AE-prevalence
.04%), plus 8 cases of abortive (=late resistant cases) E. multiloc-
laris infections (“abortive” prevalence 0.03%), and an additional
5 cases (Em2-seroprevalence 0.2%) of seroconversion following
 very likely E. multilocularis infection without subsequent para-
itological and clinical development of AE (=early resistant cases).
nterestingly, the overall seroprevalence of 0.2% of all studies com-
ined matches that of the Swiss study used above to estimate the
isease occurring.
Conclusively, we can postulate that approximately 4 out of 5 AE-
eropositive “resistant” people do not develop any visible hepatic
esion (i.e. early stage resistance or “AE-abortion”), while one out
f 5 people will “abort” only at a later stage, allowing an initial
presumably asymptomatic) lesion formation that subsequently
borted and led to the formation of one or more calciﬁed structures
pparent in US and/or CT (Rausch et al., 1987; Bresson-Hadni et al.,
994; Gottstein et al., 2001). Although this calculative approach to
nswer some of the key questions of susceptibility versus resistance
emains at a very rough and descriptive level, we  are convinced
hat it approximately reﬂects the situation in the ﬁeld, and respec-
ive conclusions may  be of preliminary value for clinicians dealing
ith diagnostic and epidemiological aspects of AE. Based on our
eﬂections on the matter, we invite epidemiological AE specialists
o take care of these considerations and to develop appropriate
athematical approaches to provide a more scientiﬁcally based
ocumentation of the ratios between the different forms of E. mul-
ilocularis infection in humans.dered as innate resistant, and can, by deﬁnition, not be included in an estimative
2. Biology and immunology of susceptibility versus
resistance in AE
In infected humans, the E. multilocularis metacestode (larva)
develops primarily in the liver. In immunocompetent individu-
als, a granulomatous host reaction surrounds the metacestode,
including a vigorous synthesis of ﬁbrous and germinative tissue.
Depending on the type of immune response elicited by the host,
infections will have different outcomes (Fig. 1): (i) seroconversion
takes place, but the parasite fails to establish chronic infection, and
either no lesions, or only “dying” or “aborted” lesions are detected;
(ii) seroconversion takes place, and metacestodes grow slowly and
establish a chronic infection, and ﬁrst clinical symptoms occur
putatively after 5–15 years post-infection, and (iii) uncontrolled
and rapid metacestode proliferation, as it occurs in individuals with
impaired immunity such as AIDS patients or patients undergoing
transplantation or being treated by immunosuppressive drugs or
biological agents.
Human patients suffering from chronic AE exhibit a rather Th2-
dominated immunity associated with an increased susceptibility
to disease. In contrast, a Th1-biased immune response induces
protective immunity, which may  even lead to aborted forms of
infection. In most AE cases investigated, a mixed Th1/Th2 proﬁle
is found during the chronic stage of disease (Hübner et al., 2006)
associated with the expression of pro-inﬂammatory cytokines in
the periparasitic granuloma and partial/relative protective immu-
nity (restriction of parasite growth) through ﬁbrosis and necrosis
(Bresson-Hadni et al., 1990). In terms of cytokine proﬁles, a Th2-
or anti-inﬂammatory-associated response, respectively, against E.
multilocularis in the immunocompetent but still susceptible host
encompasses high production of IL-5 (Sturm et al., 1995) and IL-
10 (Godot et al., 1997; Dreweck et al., 1999), respectively, while in
relatively resistant hosts the Th1-cytokine proﬁle is dominated by
IFN- (Godot et al., 2003) and IL-12 (Emery et al., 1998) as initi-
ating cytokines, and IFN- (Liance et al., 1998) and TNF- (Amiot
et al., 1999; Shi et al., 2004) as effector cytokines. Recently, the
discovery of the IL-17 cytokine family has added a new dimen-
sion to the balance of inﬂammation and tolerance during parasitic
infections. A recent study involving human AE patients showed
that increased IL-17A expression was associated with protection,
while upregulation of IL-17F expression might contribute to both
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rotection and pathogenesis (Lechner et al., 2012). IL-10 (Harraga
t al., 2003) was  found to be abundant in the periparasitic gran-
loma surrounding E. multilocularis metacestodes in the liver, as
ell as immuno-modulating TGF- (Wang et al., 2014). Explor-
ng TGF- in its multiple functions in E. multilocularis infection is,
owever, still a relatively open ﬁeld of research. There is evidence
hat TGF-1, besides its role in immune tolerance, is an extremely
otent inducer of the synthesis of procollagen and other extra-
ellular matrix components as well as in (Bartram and Speer, 2004),
nd has an essential role in the pathogenesis of liver ﬁbrosis. Such
echanisms could also play an important role in AE, as ﬁbrosis and
ollagenosis are hallmarks of AE-immunopathology (Wang et al.,
013; Vuitton et al., 2006; Vuitton and Gottstein 2010). The major
ignalling pathway for all TGF- members is activated through lig-
nd binding to a cell-surface receptor complex of type I and type
I serine–threonine kinases receptors; and a group of intracellular
ignalling intermediates known as Smads is then phosphorylated.
hosphorylated Smads translocate to the nucleus where they func-
ion as transcription factors, initiating target gene transcription
Banas et al., 2006). The relationship between the TGF-/Smad
athway, and especially the expression of Smad7, which may  play
 regulatory role in the system, and clinical and/or pathological fea-
ures of AE in experimental models as well as in human AE has been
xploratively addressed by Wang et al. (2013) and recently also by
ang et al. (2014). Other studies on the immunopathology of AE
evealed that CD4+CD25+ Treg cells play a critical role in human AE
y blunting immune responses to speciﬁc antigens, or by suppress-
ng the secretion of proinﬂammatory cytokines, especially through
L-10 and TGF-1 (Hübner et al., 2006).
Mice, as the natural intermediate hosts, represent an excellent
odel to study the immunology of AE. Conventional experimental
nfection, leading to secondary AE, is performed by intraperi-
oneal or intra-hepatic inoculation of E. multilocularis metacestode
esicles. These pre-formed metacestodes are protected by the
urface-associated and carbohydrate-rich laminated layer (LL)
Gottstein et al., 2002; Díaz et al., 2011). Immunocompetent
ice respond immunologically, but in a strain-dependent man-
er (Matsumoto et al., 2010). It was shown that impairment of
ellular immunity (immune suppression) in mice is followed by
n increase in susceptibility to E. multilocularis (Baron and Tanner,
976) and this was further conﬁrmed in SCID mice (Playford and
amiya, 1992) and in nude mice (Dai et al., 2004). A similar increase
f susceptibility, associated with a decrease of delayed type hyper-
ensitivity was also observed in E. multilocularis infected mice
reated with ciclosporin, which interferes in IL-2 production by T-
ells (Liance et al., 1992). Principally, upon experimental infection,
mmunocompetent mice elicit a cell-mediated immune response,
hich is so far inefﬁcient as it impairs, but does not inhibit, the
roliferation of the metacestode (Dai et al., 2004; Mejri et al.,
010). It has been shown that the type of the primary immune
esponse toward infection, initially Th1-oriented, got progressively
h2-oriented (Mejri et al., 2011a) during the progressive growth
f the metacestode, leading to the chronic stage of AE. Concomi-
antly, intraperitoneal dendritic cells (DCs) and T cells isolated at
his late stage of infection expressed relatively high levels of TGF-
 mRNA, while IFN- mRNA, and the surface expression of the
ajor costimulatory molecules CD80, CD86, CD40 and the MHC
lass II (Ia) molecules were downregulated (Mejri et al., 2011a,b).
t became evident that the intraperitoneally proliferating metaces-
ode abrogated maturation and activation of DCs. Therefore, DCs in
. multilocularis-infected mice were classiﬁed as tolerogenic cells,
nd moreover, as cells with suppressive features based upon their
igh level of TGF--expression.
Subsequent series of experiments showed that CD4+ T cell hypo-
esponsiveness was associated with differentiation of Treg cells
Mejri et al., 2011a). The most widely described suppressor T cellsitology 213 (2015) 103–109
are CD4+CD25+ T cells. At the late stage of experimental infec-
tion, a ﬁve-fold increase in CD4+CD25+ T cells in infected mice
became apparent, when compared to non-infected mice (Mejri
et al., 2011a). Foxp3, a marker for Treg cells, was  expressed at higher
levels in CD4 T cells and CD8+ T cells of AE-infected mice when com-
pared to non-infected mice. The high expression level of TGF- in
infected mice thus seemed to largely contribute to the development
of regulatory CD4+CD25+Foxp3+ T cells and CD8+CD25+Foxp3+ T
cells (Mejri et al., 2011a). Tregs appear thus as key immunomodula-
tors in murine AE, associated with impaired MØ and DC functions.
In a recent study (Wang et al., 2014), IL-4 expression could be
determined very soon after primary infection of mice (2–8 days).
Conclusively, Th2 markers appear to be present earlier than antic-
ipated in previous studies.
In the frame of very recent investigations on immunomodula-
tion in AE, the role of FGL2 (ﬁbrinogen-like protein 2) as another
key parameter in the Treg-dependent downregulation of peripar-
asitic immunity was addressed. Principally, FGL2 is a member of
the ﬁbrinogen-related superfamily of proteins secreted by T cells,
is highly expressed in Tregs, and has an important role in Treg cell
effector function (Levy et al., 2000). Micro-array studies showed
that FGL2 expression is signiﬁcantly up-regulated in the liver of E.
multilocularis-infected mice (Gottstein et al., 2011). Upon use of E.
multilocularis-infected fgl2-deﬁcient mice (as compared to infected
WT  mice), a signiﬁcantly lower parasite load and a reduced pro-
liferation activity was  observed, associated with increased T cell
proliferation in response to ConA, reduced Treg numbers and func-
tion, relative Th1 polarisation, and increased B cell numbers and DC
maturation (Wang et al., 2015). It became also evident, for the ﬁrst
time, that FGL2 is involved in immune regulatory processes favor-
ing larval helminth parasite survival, and that IL-17A contributes to
FGL2 regulation. By promoting Treg cell activity, FGL2 appears thus
as one of the key-players in orchestrating the immunomodulation
that permits chronic AE (summarized schematic presentation of
FGL2 function in Fig. 2).
3. Parasite antigens involved in host-parasite interactions
Predominantly excretory/secretory (E/S) metabolic products of
the E. multilocularis metacestode are considered to be important
key players in the host parasite interplay. A neutral glycosph-
ingolipid of E. multilocularis was  identiﬁed as a suppressor of
human PBMCs (peripheral blood mononuclear cells) prolifera-
tion following stimulation by phytohemagglutinin (Persat et al.,
1996). Huelsmeier et al. (2002) isolated novel mucin-type glyco-
forms from the E. multilocularis metacestode laminated layer. E.
multilocularis-protoscolex-associated proteins of 62, 70 and 90 kDa
and several recombinant E. multilocularis-proteins have all been
published and discussed in view of their potential interactive bio-
logical functions (reviewed by Huelsmeier et al., 2002).
In vitro experiments using the larval stage of the parasite,
coupled to genomic data (Brehm and Spiliotis, 2008; Brehm
2010) indicated that a series of evolutionarily conserved signaling
molecules are able to functionally interact with corresponding host
cytokines. Förster et al. (2011) demonstrated that E. multilocularis
expresses a set of nuclear receptors, one of which (EmNHR1) cross-
communicates with TGF- signaling components. More recently,
the Würzburg research group of Klaus Brehm showed that EmACT,
a secreted metacestode activin, was able to induce expansion of
host Treg cells, and thus appears to have an important role in
immunomodulation (Nono, 2012). Another parasite factor named
EmTIP, homologous to mammalian T-cell immunomodulatory pro-
tein (TIP), was  detected in secretory fractions of E. multilocularis
primary cell cultures (Nono et al., 2014). EmTIP blockade inhibited
the proliferation of E. multilocularis primary cells and the formation
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Fig. 2. The role of FGL2 in immune regulation: schematically presented hypothesis for its involvement in the host-parasite relationship. E. multilocularis metabolites induce
release of IL-6, TNF-, IFN- and IL-17; IFN- and IL-17A contribute to FGL2 secretion by Tregs and other cells; once FGL2 is released, it binds to FcRIIB receptors, down-
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megulate the maturation of DCs, decrease co-stimulation of effector T cells, suppress
ell  death, and thus overall lead to an immune suppressed status that favours the c
f metacestode vesicles in vitro, suggesting that this protein is func-
ionally important for parasite development. Also, EmTIP evoked a
trong release of IFN- by CD4+ T-cells, hence suggesting that the
ecretion of this factor could “secondarily” induce a potentially pro-
ective Th1 response. Prospectively, secretory products of worms  as
hose described above offer a novel platform for the development
f safe and effective strategies for the treatment of autoimmune
nd/or inﬂammatory disorders (Pineda et al., 2014).
. Tools to assess parasite viability in vivo
Progression of lesions, at least in immunocompetent patients,
s extremely slow in AE, and a prolonged follow-up is necessary
efore stating about regression or progression, and especially also
o assume a dying-out status of the AE lesion, which may  result in
brogation of continuous medication. Calciﬁcation of lesions, and
ts increase which indicates efﬁcient protective immune response
ith subsequent degeneration of the parasite, cannot be used
nly as a reliable marker of parasite death in the whole lesion
Wang et al., 2011). (18F)-ﬂuorodeoxyglucose (FDG) is currently the
nique validated tracer of AE lesions in positron emission tomog-
aphy (PET); it was proposed 15 years ago to assess progression of
esions, if positive, and as a marker of parasite abortion and thus
ndication of benzimidazole withdrawal, if negative (Reuter et al.,
999, 2004). This approach has proved efﬁcient in several patients,
ut drug withdrawal was followed by recurrence in some of them
Reuter et al., 2004; Stumpe et al., 2007). Improvement in the PET
maging procedure, better adapted to the speciﬁc situation of AE has
een proposed: it is now accepted that PET may  only be considered
egative if images acquired 3 h (and not only 1 h) after FDG injec-
ion are negative (Caoduro et al., 2013). In fact, FDG–PET images do
ot directly reﬂect parasite viability but rather peri-parasitic host
nﬂammatory process. The ideal PET tracer should be able to assess
he course of AE upon direct uptake by the metacestode through
ts metabolic activity (Porot et al., 2013) or by binding to parasite
olecules that are only accessible in viable metacestodes. This isnd Th17 immune response, accelerate Th2 immune responses, induce apoptotic B
ous “tumour-like” progression of the parasitic metacestode.
supported by the fact that FDG uptake can be visualised only in
those areas where the periparasitic inﬁltrate by immune cells is
dense, and by the observation that in vitro uptake of FDG by leuko-
cytes is far more efﬁcient than FDG uptake by E. multilocularis cells
or vesicles (Porot et al., 2014). Preliminary results from the ret-
rospective comparison between MR  and FDG–PET images showed
that identiﬁcation of micro-vesicles in AE lesions by MRI  highly sug-
gests ‘metabolically active’, hence viable, metacestode (Azizi et al.,
2014); however, before being reliably used as a marker, studies on a
larger cohort of patients with and without anti-parasite treatment
withdrawal, will be necessary, as claimed by the authors.
If biopsies or ﬁne-needle aspirates are available from AE
patients, testing of parasite viability can be performed with RT-PCR
upon various constitutively expressed gene targets (e.g. 14-3-3)
(Diebold-Berger et al., 1997), however, limits of this method pri-
marily relate to sampling site and methodical approach used to
isolate mRNA and subsequent procedures (Ito and Craig, 2003;
Matsumoto et al., 2006; Yamasaki et al., 2007). However, due to
these limits, such an invasive technique cannot yet be recom-
mended for routine follow-up. In addition to PET–CT, some speciﬁc
serologic tests proved valuable to assess the efﬁcacy of treatment of
AE patients (Siles-Lucas and Gottstein, 2001; Ito and Craig, 2003).
Disappearance of IgE and IgG4 isotypes of anti-Echinococcus spe-
ciﬁc antibodies were reported to be associated with good prognosis
and absence of recurrence after surgery and chemotherapy in AE
patients. This was conﬁrmed in another series of patients, which
also showed that in AE patients with progressive disease, IgG4 dis-
tinctively recognised low molecular mass antigens of Mr 26 kDa,
18 kDa, 16 kDa and 12 kDa (reviewed in Schweiger et al., 2007). In
a more recent study, E. multilocularis metacestode-speciﬁc IgG1,
IgG3, and IgE responses progressively diminished with regression
from active to stable and cured AE, and IgG2 and IgG4 reactiv-
ity remained similarly high in stable and progressive cases, and
lessened only with cured AE (Huang et al., 2014). However, such
isotype determinations do not seem to have entered routine follow-
up of AE patients, and should perhaps be evaluated further in a
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arger series of patients. After successful surgery and/or chemother-
py leading to inactivation of the parasite, anti-Em18 (and to a
ertain extent anti-Em2+) antibodies rapidly decline, and sero-
onversion to undetectable levels correlates well with curative
esection (Ammann et al., 2004; Tappe et al., 2010; Bresson-Hadni
t al., 2011).
. Conclusions and outlook
The response characteristics of AE-resistant people could so
ar not be elucidated. One already knows that impairment of
h1 cell activity is associated with a rapid and unlimited growth
nd dissemination of the parasite in AE, and that CD4+ recov-
ry/reconstitution by means of appropriate therapy (such as shown
n an AE-infected AIDS patient (Zingg et al., 2004), reinstated
ontrol over progression of AE treated with benzimidazoles. The
emaining challenge is now to ﬁnd out which type of immunother-
peutical intervention could redirect the immunity of AE patients
oward improved control of metacestode proliferation. Ideally,
uch an intervention should lead to a “dying-out-status” of the
etacestodes by matching that immune proﬁle developed by nat-
rally resistant people.
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